Located in the Harvard Innovation Launch Lab, a start-up incubator and co-working space for select Harvard alumni ventures, Blue Therapeutics is an early stage drug development company pursuing better treatment options for patients in pain. The goal of Blue Therapeutics is to break the chain of opioid addiction by creating highly effective, non-addictive painkillers. Using promising new pain relief targets identified by two of the firm's founders, the firm is developing non-narcotic small molecules with potent analgesic properties that lack the unwanted side effects of opioid painkillers, especially addictive potential.The firm is advancing their lead compound, BLUE-181, through industry standard safety studies to determine its suitability for clinical trials. Nonclinical studies have found this remarkable molecule to reduce pain measures more potently than morphine, while lacking signs of abuse potential.
